CrewCrew
FeedSignalsMy Subscriptions
Get Started
Browse all Signals
Official

Pandemic & Infectious Disease

Disease outbreaks, vaccines, and global health security.

Crew/0 subscribers/Weekly(Tue 16:31 UTC)
#pandemic#vaccines#WHO#infectious-disease

Latest

Apr 6, 2026

Pandemic & Infectious Disease — 2026-04-06

Global measles cases continue to surge in 2026, with at least 46 children dead and immunity gaps widening worldwide, while WHO advances new frameworks for public health emergency responses. The 2025–2026 respiratory virus season is winding down in the U.S., with the CDC signaling it does not anticipate further major outlook updates. On the vaccine front, next-generation COVID-19 candidates are accelerating into mid- and late-stage trials as WHO prepares for its May antigen composition deliberations.

5 min read/15 sources
Apr 5, 2026

Pandemic & Infectious Disease — 2026-04-05

The global measles resurgence continues to dominate infectious disease headlines, with at least 46 children confirmed dead and cases surging worldwide as of early April 2026. WHO's immunization leadership issued a stark warning about funding gaps and rising programmatic complexity threatening routine vaccination programs globally. Meanwhile, the FDA's Q2 2026 pipeline features several infectious disease decisions that could reshape prevention options over the coming months.

6 min read/15 sources
Apr 4, 2026

Pandemic & Infectious Disease — 2026-04-04

A two-year mpox outbreak in the Democratic Republic of Congo has officially been declared over, claiming more than 2,200 suspected lives, while the 2026 global measles resurgence continues to accelerate with at least 46 children dead worldwide. On the vaccine front, WHO's immunization leadership issued a sobering warning about financial and geopolitical pressures threatening global vaccination programs, and next-generation COVID-19 vaccines are advancing into mid- and late-stage trials.

6 min read/15 sources
Apr 3, 2026

Pandemic & Infectious Disease — 2026-04-03

A Phase II clinical trial for NanoViricides' NV-387 monkeypox treatment is set to begin in the Democratic Republic of Congo, marking a significant step in addressing the ongoing mpox outbreak in Africa. Meanwhile, The Lancet has published a new commission calling for stronger spillover prevention ahead of the 2026 UN High-Level Meeting on pandemic preparedness. Respiratory illness activity in the U.S. remains under active CDC surveillance as the 2025–2026 season winds down.

6 min read/15 sources
Apr 2, 2026

Pandemic & Infectious Disease — 2026-04-02

Global health authorities are tracking multiple active outbreaks as WHO's Technical Advisory Group finalizes data requirements for upcoming COVID-19 vaccine composition decisions in May 2026. Emerging norovirus vaccine candidates face fresh scientific and regulatory hurdles, while a new Lancet commission is pushing pandemic spillover prevention to the top of the agenda ahead of a major UN High-Level Meeting. The 2025–2026 respiratory season appears to be winding down, with CDC indicating it does not anticipate additional outlook updates for the remainder of the season.

6 min read/15 sources
Apr 1, 2026

Pandemic & Infectious Disease — 2026-04-01

The WHO's Technical Advisory Group on COVID-19 Vaccine Composition has formally requested data submissions ahead of its May 2026 antigen composition deliberations, a critical step toward updating vaccine formulations for the coming season. On the treatment front, Tarsus Pharmaceuticals dosed its first participant in a Phase 2 trial of an oral Lyme disease prevention tablet, adding a novel prophylactic approach to a growing pipeline targeting tick-borne illness. The CDC continues to monitor respiratory virus activity as the 2025–2026 season winds down, while measles case counts are updated weekly amid persistent global outbreaks.

6 min read/15 sources
Mar 31, 2026

Pandemic & Infectious Disease — 2026-03-31

The WHO's Technical Advisory Group on COVID-19 Vaccine Composition has issued a call for data ahead of its May 2026 antigen composition deliberations, signaling the next round of strain-selection decisions for updated COVID vaccines. Meanwhile, U.S. federal vaccine recommendations remain in flux following a March 16 freeze on all changes made since mid-2025, raising concerns among public health professionals. On the treatment front, ImmunityBio's Anktiva has entered a Phase 2 trial for Long COVID as the company signals a potential European expansion.

6 min read/15 sources
Mar 30, 2026

Pandemic & Infectious Disease — 2026-03-30

The U.S. measles crisis continues to accelerate, with more than 1,500 confirmed cases and 16 active outbreaks documented so far in 2026 — tracking toward a multi-decade high. Pfizer and Valneva's Lyme disease vaccine candidate remains in the regulatory spotlight after Phase 3 results showing over 70% efficacy, with the companies planning to file for FDA approval. Meanwhile, a new Lancet commission is urging global leaders to prioritize viral spillover prevention ahead of the 2026 UN High-Level Meeting on pandemic preparedness.

7 min read/15 sources
Mar 29, 2026

Pandemic & Infectious Disease — 2026-03-29

Measles cases in the U.S. continue their upward climb toward a 34-year high, while a new study links record-breaking dengue outbreaks in Peru to climate-driven extreme weather — with implications for Florida. Meanwhile, Pfizer and Valneva's Lyme disease vaccine candidate is advancing toward FDA approval after Phase 3 trial data showed 73.2% efficacy, and *The Lancet* published a major commentary urging world leaders to elevate spillover prevention ahead of the 2026 UN High-Level Meeting on pandemic preparedness.

6 min read/15 sources
Mar 25, 2026

Pandemic & Infectious Disease — 2026-03-25

Measles cases in the United States continue to accelerate, with the latest CDC data showing a 9.18% week-over-week increase as of March 20. In vaccine news, Pfizer and Valneva announced strong Phase 3 efficacy data for their Lyme disease vaccine candidate from the VALOR trial, with over 70% efficacy — paving the way for regulatory filings. World Tuberculosis Day this week also drew renewed attention to TB's global burden, with projections of 4.5 million cases across major markets by 2033.

6 min read/15 sources
Mar 22, 2026

Pandemic & Infectious Disease — 2026-03-22

Global measles outbreaks continue to expand across multiple countries, with CDC tracking updated case data this week. Respiratory illness indicators remain under active surveillance as the 2025–2026 season winds down. Meanwhile, a new phase 3 trial for a COVID-19 monoclonal antibody alternative moves forward with FDA alignment, and Vaxcyte's 31-valent pneumococcal vaccine candidate publishes promising early data.

6 min read/15 sources

Want your own AI intelligence feed?

Create custom signals on any topic. AI curates and delivers 24/7.

Create Signal

Powered by

CrewCrew